Incyte
| Public | |
| Traded as | NASDAQ: INCY |
| Industry | pharmaceutical company |
| Founded | 1991 |
| Headquarters | Wilmington, Delaware, United States |
Key people | Hervé Hoppenot (President and CEO, 2014) |
| Revenue | ~US$94.5 million (2011) |
| ~(US$186.5 million) (2011) | |
| Total assets | ~US$329 million (2011) |
| Total equity | ~(US$227 million) (2011) |
Number of employees | ~600[1] |
| Website |
www |
|
Footnotes / references [2] | |
Incyte, Corp is a pharmaceutical company based in Alapocas, Delaware.[3] Incyte has one drug which has been approved by the U.S. Food and Drug Administration (FDA) and has been prescribed to several thousands of patients in the United States, Jakafi.[3]
Incyte was founded in Palo Alto, California in 1991. The company went public in 1993.[1]
The company is working on an investigational drug for rheumatoid arthritis in partnership with Eli Lilly, called baricitinib.[4] The drug is in phase III clinical trials.
In 2014, Incyte named Hervé Hoppenot to the posts of President and CEO.[5] Hoppenot had previously served as the President of Novartis Oncology; he had been with Novartis since 2003.[5]
References
- ↑ 1.0 1.1 Scott Goss (2 Mar 2015). "Incyte is Delaware Bio Company of the Year, again". delawareonline.com. Retrieved 2 Mar 2015.
- ↑ Incyte Corporation (2012), Form 10-K (SEC filing), Incyte Corporation (published February 22, 2012), Commission File Number: 0-27488, retrieved May 6, 2012
- ↑ 3.0 3.1 Natoli, Cori Anne (May 5, 2012), "Incyte looks to ride on drug's success", The News Journal, retrieved May 6, 2012
- ↑ "Lilly, Incyte Treatment Shows Positive Results". www.insideindianabusiness.com. 9 Dec 2014. Retrieved 2 Mar 2015.
- ↑ 5.0 5.1 "People". Gen. Eng. Biotechnol. News (paper) 34 (4). February 15, 2014. p. 41.